For example, an increase in CD8+CD28− Tregs has been seen to correlate with poor prognosis in metastatic cancer patients receiving T-lymphocyte immunotherapy following chemotherapy [81], and the expression of CD39 on CD8+ Tregs has been linked to the evasion of the antitumor immune response [82]. The gene discussed is CD8A; the disease is metastatic malignant neoplasm.